<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191903</url>
  </required_header>
  <id_info>
    <org_study_id>Cingal 16-02</org_study_id>
    <nct_id>NCT03191903</nct_id>
  </id_info>
  <brief_title>Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide</brief_title>
  <official_title>Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal™) to Provide Symptomatic Relief of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, parallel group, active comparator&#xD;
      controlled trial to evaluate the efficacy and safety of a single injection of Cingal for the&#xD;
      relief of joint pain in subjects with OA of the knee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Actual">April 23, 2018</completion_date>
  <primary_completion_date type="Actual">April 23, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline WOMAC pain score</measure>
    <time_frame>26 weeks</time_frame>
    <description>• The change from baseline in knee pain as measured by the WOMAC Pain Score (100 mm VAS) at 26 weeks post treatment comparing the Cingal group to the TH group.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">576</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Cingal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monovisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Hexacetonide (TH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)</description>
    <arm_group_label>Cingal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monovisc</intervention_name>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose</description>
    <arm_group_label>Monovisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Hexacetonide</intervention_name>
    <description>20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide</description>
    <arm_group_label>Triamcinolone Hexacetonide (TH)</arm_group_label>
    <other_name>TH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Screening Inclusion Criteria&#xD;
&#xD;
               1. Subject is 40-75 years old, with a Body Mass Index (BMI) ≤ 40 kg/m2.&#xD;
&#xD;
               2. Subject has Kellgren-Lawrence (K-L) severity grade I, II or III in the index knee&#xD;
                  as determined by X-ray. Contralateral knee: K-L severity grade 0, I or II.&#xD;
&#xD;
               3. Subject has had at least two signs and at least two symptoms of OA disease (based&#xD;
                  on the European League Against Rheumatism (EULAR) recommendations for diagnosing&#xD;
                  knee OA) in the index knee for at least 6 months despite conservative treatment&#xD;
                  (weight reduction, physical therapy, pain medications, etc.). The EULAR signs and&#xD;
                  symptoms are as follows:&#xD;
&#xD;
                    -  Signs: crepitus, restricted movement and bony enlargement&#xD;
&#xD;
                    -  Symptoms: persistent knee pain, limited morning stiffness and reduced&#xD;
                       function&#xD;
&#xD;
               4. Subject must be willing to abstain from other IA treatments of the knee for the&#xD;
                  duration of the study.&#xD;
&#xD;
               5. Subject is willing to discontinue all analgesics including NSAIDs, except&#xD;
                  acetaminophen/paracetamol, at least seven days before the treatment injection and&#xD;
                  through the completion of the study.&#xD;
&#xD;
               6. Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0&#xD;
                  grams per day per the package insert) for the treatment of joint pain for the&#xD;
                  duration of the study. At least forty eight hours prior to the Baseline Visit and&#xD;
                  each follow-up visit, the subject is willing to discontinue use of&#xD;
                  acetaminophen/paracetamol.&#xD;
&#xD;
               7. Subject is willing to maintain a stable dose of oral glucosamine and/or&#xD;
                  chondroitin sulfate products throughout the study, if taken prior to signing the&#xD;
                  informed consent form (ICF).&#xD;
&#xD;
               8. Subject is able to understand and comply with the requirements of the study and&#xD;
                  voluntarily provides consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subject received an IA injection of Hyaluronic Acid (HA) and/or steroid in either&#xD;
             knee within 6 months of signing the informed consent form (ICF). A subject will be&#xD;
             excluded if they are planning to receive an HA or steroid injection (other than the&#xD;
             study injection) in either knee during the course of this study.&#xD;
&#xD;
             2. Subject had an arthroscopy of either knee within 3 months of signing the ICF.&#xD;
&#xD;
             3. Subject had an open surgical procedure of either knee or hip or any surgery of the&#xD;
             spine within 12 months of signing ICF. Subject plans to have knee, hip or spine&#xD;
             surgery within the study period.&#xD;
&#xD;
             4. Subject has intra-articular trauma to the index knee. Subject has concurrent&#xD;
             multi-system or multi-limb trauma.&#xD;
&#xD;
             5. Subject has evidence or medical history of the following diseases in the index&#xD;
             knee: septic arthritis; inflammatory joint disease; history of Reiter's syndrome;&#xD;
             gout; chondrocalcinosis associated with recurrent episodes of acute synovitis of the&#xD;
             knee consistent with pseudogout; osteochondritis dissecans, Paget disease of the bone;&#xD;
             ochronosis; acromegaly; hemochromatosis; primary osteochondromatosis; known history of&#xD;
             Wilson disease; heritable disorders or collagen gene mutations.&#xD;
&#xD;
             6. Subject has a history of cartilage repair surgery in the index knee within 3 years&#xD;
             of signing the ICF.&#xD;
&#xD;
             7. Subject has a history of ACL repair, reconstruction or injury in the index knee&#xD;
             within 3 years of signing the ICF.&#xD;
&#xD;
             8. Subject has X-ray findings of acute fractures, severe bone loss, avascular&#xD;
             necrosis, severe bone or joint deformity in the index knee.&#xD;
&#xD;
             9. Subject has significant varus or valgus deformity greater than 10 degrees in either&#xD;
             knee.&#xD;
&#xD;
             10. Subject has a clinically apparent tense effusion of the index knee. 11. Subject&#xD;
             has knee instability in either knee per the Investigator's assessment.&#xD;
&#xD;
             12. Subject requires consistent use of an assistive device (e.g. wheelchair, walker,&#xD;
             etc.) Occasional use of a cane is acceptable.&#xD;
&#xD;
             13. Subject has medical condition(s) which could affect study assessments or may&#xD;
             adversely affect the safety and/or success of the study treatment. This includes but&#xD;
             is not limited to the following: a. Peripheral neuropathy severe enough to interfere&#xD;
             with evaluation of the subject, b. Vascular insufficiency severe enough to interfere&#xD;
             with evaluation of the subject, c. Active fibromyalgia, d. Hemiparesis involving&#xD;
             either lower extremity, e. Immunocompromised or immunosuppressive disorder or&#xD;
             receiving medications to treat immunosuppressive disorders, f. Systemic bleeding&#xD;
             disorder(s), g. Current malignancy or treatment within the last 5 years, except for&#xD;
             non-melanoma skin cancer, h. Significant psychiatric disorder, i. Active drug and/or&#xD;
             alcohol abuse within the past year, j. Uncontrolled diabetes with a screening HbA1c of&#xD;
             &gt;7%.&#xD;
&#xD;
             14. Subject is taking medications at the time the subjects signs the ICF which could&#xD;
             interfere with the treatment procedure, healing and/or assessments. This includes but&#xD;
             is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet&#xD;
             treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular&#xD;
             protection is allowed if a stable regimen is maintained for the duration of the study.&#xD;
&#xD;
             15. Subject is receiving treatment using electromagnetic stimulation and/or low&#xD;
             intensity ultrasound in the index knee at the time of signing the ICF, within 3 months&#xD;
             of signing the ICF or plans to receive treatment any time during the study period.&#xD;
&#xD;
             16. Subjects who had an oral, intramuscular, intravenous, rectal suppository or&#xD;
             topical (excluded in index knee only) corticosteroid within 30 days of signing the ICF&#xD;
             are excluded. Topical corticosteroid use at any site other than the index knee is&#xD;
             allowed.&#xD;
&#xD;
             17. Subject has a pre-treatment contraindication to IA injections or aspiration of the&#xD;
             index knee, including cutaneous infection in the injection site area, active IA&#xD;
             infection (as suggested by moderate or marked effusion), knee deformity or condition&#xD;
             which, in the opinion of the Investigator could jeopardize the sterility or delivery&#xD;
             of the IA injection.&#xD;
&#xD;
             18. Subjects with a history of hypersensitivity to any of the ingredients in the&#xD;
             hyaluronan or previous hypersensitivity to the administration of corticosteroids or an&#xD;
             inability to tolerate acetaminophen/paracetamol.&#xD;
&#xD;
             19. Subject has any contraindication to the receipt of a corticosteroid. 20. Subject&#xD;
             is receiving or in litigation for worker's compensation. 21. Subject is a woman who is&#xD;
             pregnant or breastfeeding at the Screening Visit or a woman of child bearing potential&#xD;
             who refuses to use effective contraception during the course of the study.&#xD;
&#xD;
             22. Subject was involved in any other research study involving an investigational&#xD;
             product, or a new application of an approved product, within 60 days of signing the&#xD;
             ICF.&#xD;
&#xD;
        Baseline Inclusion Criteria&#xD;
&#xD;
        1. Subject has a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)&#xD;
        pain-sub-score ≥ 40 mm and ≤ 90 mm in the affected knee and ≤ 30 mm in the contralateral&#xD;
        knee on a 100 mm Visual Analog Scale (VAS) scale.&#xD;
&#xD;
        Baseline Exclusion Criteria&#xD;
&#xD;
          1. Subject has a decrease of ≥ 20 mm in the WOMAC pain-sub-score (average of 5 pain&#xD;
             scales) from Screening to Baseline in the index knee on a 100 mm Visual Analog Scale&#xD;
             (VAS) scale.&#xD;
&#xD;
          2. Subject has a synovial fluid aspirate volume &gt; 20 mL in the index knee.&#xD;
&#xD;
          3. Subject has a contraindication to continue with the study treatment injection based on&#xD;
             the visual appearance of the synovial fluid aspirate unless the fluid is examined&#xD;
             microscopically prior to injection with no clinically significant findings (e.g.&#xD;
             bacteria, crystals or blood).&#xD;
&#xD;
          4. Subject has range of motion of less than 100° flexion in either knee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo Hangody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uzsoki Hospital, Department of Traumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baleseti Központ</name>
      <address>
        <city>Budapest,</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Center of Downtown-Lipotvaros, Orthopedic Outpatient Clinic (Belvárosi-Lipótvárosi Egészségügyi Szolgálat Ortopeadia)</name>
      <address>
        <city>Budapest</city>
        <zip>1051</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Kórház</name>
      <address>
        <city>Budapest</city>
        <zip>29-41</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE KK Ortopediai Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jutrix Medical Llc</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medidea Bt.</name>
      <address>
        <city>Kiskunfélegyháza</city>
        <zip>6100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kastelypark Klinka</name>
      <address>
        <city>Tata</city>
        <zip>2890</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowie Osteo-Medic</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Świętego Łukasza S.A.</name>
      <address>
        <city>Bielsko-Biała</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Medi SPATZ</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTIMED Niepubliczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne 4M Plus</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOVAMED Jackowiak Krajewski Spółka Jawna</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Amed Warszawa Targówek</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Network, Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Network</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne</name>
      <address>
        <city>Świdnik,</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 25, 2020</submitted>
    <returned>September 15, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

